(NASDAQ: BBIO) Bridgebio Pharma's forecast annual revenue growth rate of 77.89% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 78.36%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Bridgebio Pharma's revenue in 2025 is $235,812,000.On average, 8 Wall Street analysts forecast BBIO's revenue for 2025 to be $95,490,197,096, with the lowest BBIO revenue forecast at $76,868,855,458, and the highest BBIO revenue forecast at $154,196,515,326. On average, 8 Wall Street analysts forecast BBIO's revenue for 2026 to be $152,744,017,033, with the lowest BBIO revenue forecast at $118,606,674,937, and the highest BBIO revenue forecast at $214,758,697,394.
In 2027, BBIO is forecast to generate $263,794,948,018 in revenue, with the lowest revenue forecast at $216,383,629,678 and the highest revenue forecast at $341,331,363,892.